NCT00662571View on ClinicalTrials.gov

Acamprosate: Genes Associated With Response

CompletedOBSERVATIONAL
Enrollment

485

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Alcoholism
Interventions
DRUG

acamprosate

acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Samuel C. Johnson Foundation

UNKNOWN

lead

Mayo Clinic

OTHER

NCT00662571 - Acamprosate: Genes Associated With Response | Biotech Hunter | Biotech Hunter